FDA Approves First Generic Versions of Abilify

By the Editors

The FDA on Tuesday approved the first generic versions of the atypical antipsychotic Abilifiy (aripiprazole) for schizophrenia and bipolar disorder.

Like all atypical antipsychotics, generic aripiprazole will carry a boxed warning about the increased mortality risk when used off-label to treat behavioral problems in elders with dementia-related psychosis. In addition, the boxed warning notes an increased risk for suicidality in children, adolescents, and young adults also taking antidepressants.